Azithromycin
- Generic Name
- Azithromycin
- Brand Names
- Azasite, Zithromax, Zmax
- Drug Type
- Small Molecule
- Chemical Formula
- C38H72N2O12
- CAS Number
- 83905-01-5
- Unique Ingredient Identifier
- J2KLZ20U1M
- Background
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration . It was initially approved by the FDA in 1991 .
...
- Indication
Azithromycin should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria in order to prevent the development antimicrobial resistance and maintain the efficacy of azithromycin .
...
- Associated Conditions
- Acute Bacterial Sinusitis (ABS), Acute Otitis Media (AOM), Acute bacterial exacerbation of COPD caused by Haemophilus Influenza Infections, Moraxella Catarrhalis Infection, Streptococcus Pneumoniae Infections, Bacterial Conjunctivitis, Bacterial Sinusitis, Cervicitis, Chancroid, Community Acquired Pneumonia (CAP), Genital Ulcer Disease (GUD), Pelvic Inflammatory Disease (PID), Pharyngitis, Streptococcal Pharyngitis, Tonsillitis bacterial, Tonsillitis streptococcal, Traveler's Diarrhea, Uncomplicated Skin and Skin Structure Infections, Urethritis
- Associated Therapies
- -
Evaluation of Clinical and Microbial Efficacy and Safety of AzaSite Compared to Tobramycin for Bacterial Conjunctivitis (C-01-401-004)
- First Posted Date
- 2005-03-15
- Last Posted Date
- 2013-12-16
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 743
- Registration Number
- NCT00105469
- Locations
- 🇺🇸
Alan Shuster, MD, Jupiter, Florida, United States
🇺🇸Children's Eye Physicians, Littleton, Colorado, United States
🇺🇸Pasco Eye Institute, New Port Richey, Florida, United States
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
- Conditions
- First Posted Date
- 2002-08-08
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- National Center for Research Resources (NCRR)
- Target Recruit Count
- 40
- Registration Number
- NCT00043264
- Locations
- 🇺🇸
University of Texas Medical School, Houston, Texas, United States
Azithromycin/Bicillin Syphilis
- Conditions
- Interventions
- First Posted Date
- 2002-03-07
- Last Posted Date
- 2013-04-29
- Target Recruit Count
- 593
- Registration Number
- NCT00031499
- Locations
- 🇺🇸
Louisiana State University Health Sciences Center - Infectious Diseases, New Orleans, Louisiana, United States
🇲🇬Hopitaly Mahabibo, Mahajanga Majunga, Mahajanga, Madagascar
🇺🇸University of Alabama Hospital - Infectious Diseases, Birmingham, Alabama, United States
A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 850
- Registration Number
- NCT00000947
- Locations
- 🇺🇸
Washington Reg AIDS Prog / Dept of Infect Dis, Washington, District of Columbia, United States
🇺🇸Henry Ford Hosp, Detroit, Michigan, United States
🇺🇸Richmond AIDS Consortium / Div of Infect Diseases, Richmond, Virginia, United States
A Study of Azithromycin in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT00002344
- Locations
- 🇺🇸
Harris Laboratories Inc, Phoenix, Arizona, United States
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002139
- Locations
- 🇺🇸
Ctr for Phase I Research, Wichita, Kansas, United States
A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002140
- Locations
- 🇺🇸
Dr Milton Estes, Mill Valley, California, United States
🇺🇸Santa Clara Valley Med Ctr, San Jose, California, United States
🇺🇸Whitman - Walker Clinic, Washington, District of Columbia, United States
An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS)
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002090
- Locations
- 🇺🇸
Beth Israel Hosp, Boston, Massachusetts, United States
🇺🇸Audie L Murphy Veterans Administration Hosp, San Antonio, Texas, United States
🇺🇸Ohio State Univ Hosp, Columbus, Ohio, United States
A Study to Evaluate the Safety and Efficacy of Azithromycin in Individual Patients With Serious Nontuberculous Mycobacterial Disease Who Are Failing or Intolerant of Other Available Therapy
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002085
- Locations
- 🇺🇸
Natl Cancer Institute / Metabolism Branch, Bethesda, Maryland, United States
🇺🇸Pfizer Central Research, Groton, Connecticut, United States
A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients
- Conditions
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- Pfizer
- Registration Number
- NCT00002309
- Locations
- 🇺🇸
United States Air Force Med Ctr, Lackland Air Force Base, Texas, United States
🇺🇸San Diego Naval Hosp, San Diego, California, United States
🇺🇸Womack Army Med Ctr / Med Clinic, Fort Bragg, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.